[Form 4] Tonix Pharmaceuticals Holding Corp. Insider Trading Activity

Rhea-AI Filing Summary

Tonix Pharmaceuticals (TNXP) director James Treco purchased 250 shares of the companycommon stock on 08/20/2025 at a reported price of $36 per share. Following the purchase, Mr. Treco directly beneficially owned 250 shares. The transaction was reported on a Form 4 and signed by an attorney-in-fact.

Positive

• Insider purchase reported by a director, which provides transparency into insider activity
• Direct beneficial ownership is clearly disclosed (250 shares), reducing ambiguity about control

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: A small, routine insider buy by a director that is unlikely to change governance dynamics.

The reported purchase of 250 shares at $36 each is a minor insider purchase in absolute terms and represents direct ownership rather than an indirect stake. For a public company, this size of acquisition does not materially affect control or board influence. The filing is procedural and conforms to Section 16 reporting requirements.

Securities Analyst

TL;DR: Transaction is informational but immaterial to valuation or near-term market impact.

From a market perspective, 250 shares acquired at $36 is not material relative to typical public float sizes. The report provides transparency on insider activity but offers limited signal for investment decisions given the small share count and lack of accompanying change in ownership percentage or compensation-linked derivatives.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Treco James

(Last) (First) (Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP

26 MAIN STREET, SUITE 101

(Street)

CHATHAM NJ 07928

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001	08/20/2025		P		250	A	$36	250	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jessica Morris, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for TNXP and which insider is involved?

The reporting person is James Treco, a director of Tonix Pharmaceuticals Holding Corp.

What transaction is reported on the TNXP Form 4?

Purchase of 250 shares of common stock (non-derivative) executed on 08/20/2025 at a reported price of $36 per share.

How many Tonix (TNXP) shares does the reporting person own after the transaction?

250 shares beneficially owned following the reported purchase, held directly.

Does the Form 4 indicate indirect ownership or derivative holdings for the reporting person?

No. The filing shows a direct ownership entry for common stock and no derivative securities reported.

Was the Form 4 signed and who signed it?

The filing was signed by an attorney-in-fact, Jessica Morris, on behalf of the reporting person.